MACULA2
Commercialising a novel diagnostic panel for patient stratification in Age-related MACULAr Degeneration
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0MACULA2 project word cloud
Explore the words cloud of the MACULA2 project. It provides you a very rough idea of what is the project "MACULA2" about.
Project "MACULA2" data sheet
The following table provides information about the project.
| Coordinator |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 150˙000 € |
| EC max contribution | 150˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2016-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-12-01 to 2019-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | STICHTING KATHOLIEKE UNIVERSITEIT | NL (NIJMEGEN) | coordinator | 150˙000.00 |
Map
Project objective
'In MACULA2 we aim to develop a genetic diagnostic test for complement activation that will allow proper stratification of patients with age-related macular degeneration (AMD). AMD is an inflammatory disease, the #1 cause of blindness in the world, with 196 million patients estimated for 2020. Such a test does not currently exist, strongly hampering drug development and patient treatment. Poor patient stratification contributes to high failure rates in trials for AMD. Local and systemic inflammation in AMD are caused by deregulated activation of the alternative pathway of the complement system. In AMD, some patients have higher complement activation levels compared to controls, which stimulates further inflammation. Several complement-lowering therapies for AMD are under development. Pharmaceutical companies are aware that patients with a genetic predisposition to higher complement activation levels will potentially benefit most from such treatments. Without sound patient stratification, therapies that are currently in clinical trials may not reach the statistical significance needed for approval. However, certain individuals might actually benefit from these therapies because of their specific genetic makeup. We aim to solve the challenge of patient stratification in AMD by developing a novel diagnostic test based on genetic testing combined with a patient questionnaire. An AMD diagnostic test will contribute towards a precision medicine approach towards treatment of patients.'
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Laura Lorés-Motta, Eiko K. de Jong, Anneke I. den Hollander Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration published pages: 315-343, ISSN: 1177-1062, DOI: 10.1007/s40291-018-0332-1 |
Molecular Diagnosis & Therapy 22/3 | 2019-11-06 |
| 2018 |
Laura Lorés-Motta, Constantin C. Paun, Jordi Corominas, Marc Pauper, Maartje J. Geerlings, Lebriz Altay, Tina Schick, Mohamed R. Daha, Sascha Fauser, Carel B. Hoyng, Anneke I. den Hollander, Eiko K. de Jong Genome-Wide Association Study Reveals Variants in CFH and CFHR4 Associated with Systemic Complement Activation published pages: , ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2017.12.023 |
Ophthalmology | 2019-11-06 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MACULA2" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MACULA2" are provided by the European Opendata Portal: CORDIS opendata.